These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29890391)

  • 1. Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway.
    Renaud J; Bassareo V; Beaulieu J; Pinna A; Schlich M; Lavoie C; Murtas D; Simola N; Martinoli MG
    Neurobiol Aging; 2018 Sep; 69():117-128. PubMed ID: 29890391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease.
    Elgueta D; Aymerich MS; Contreras F; Montoya A; Celorrio M; Rojo-Bustamante E; Riquelme E; González H; Vásquez M; Franco R; Pacheco R
    Neuropharmacology; 2017 Feb; 113(Pt A):110-123. PubMed ID: 27693549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct intranigral injection of dopaminochrome causes degeneration of dopamine neurons.
    Touchette JC; Breckenridge JM; Wilken GH; Macarthur H
    Neurosci Lett; 2016 Jan; 612():178-184. PubMed ID: 26704434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
    Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
    Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-hydroxydopamine-induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis.
    Fricke IB; Viel T; Worlitzer MM; Collmann FM; Vrachimis A; Faust A; Wachsmuth L; Faber C; Dollé F; Kuhlmann MT; Schäfers K; Hermann S; Schwamborn JC; Jacobs AH
    Eur J Neurosci; 2016 May; 43(10):1352-65. PubMed ID: 26950181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease.
    Zhang Y; Wu IW; Buckley S; Coffey CS; Foster E; Mendick S; Seibyl J; Schuff N
    Mov Disord; 2015 Aug; 30(9):1229-36. PubMed ID: 25920732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The degeneration of dopaminergic synapses in Parkinson's disease: A selective animal model.
    Morales I; Sanchez A; Rodriguez-Sabate C; Rodriguez M
    Behav Brain Res; 2015 Aug; 289():19-28. PubMed ID: 25907749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue engineered nigrostriatal pathway for treatment of Parkinson's disease.
    Struzyna LA; Browne KD; Brodnik ZD; Burrell JC; Harris JP; Chen HI; Wolf JA; Panzer KV; Lim J; Duda JE; España RA; Cullen DK
    J Tissue Eng Regen Med; 2018 Jul; 12(7):1702-1716. PubMed ID: 29766664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat.
    González-Hernández T; Barroso-Chinea P; Rodríguez M
    Mov Disord; 2004 Sep; 19(9):1029-1042. PubMed ID: 15372592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acetyl-L-Carnitine via Upegulating Dopamine D1 Receptor and Attenuating Microglial Activation Prevents Neuronal Loss and Improves Memory Functions in Parkinsonian Rats.
    Singh S; Mishra A; Srivastava N; Shukla R; Shukla S
    Mol Neurobiol; 2018 Jan; 55(1):583-602. PubMed ID: 27975173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
    ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manganese exposure exacerbates progressive motor deficits and neurodegeneration in the MitoPark mouse model of Parkinson's disease: Relevance to gene and environment interactions in metal neurotoxicity.
    Langley MR; Ghaisas S; Ay M; Luo J; Palanisamy BN; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Neurotoxicology; 2018 Jan; 64():240-255. PubMed ID: 28595911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
    Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
    PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson's disease mouse model.
    Lv YQ; Yuan L; Sun Y; Dou HW; Su JH; Hou ZP; Li JY; Li W
    Transl Neurodegener; 2022 Mar; 11(1):14. PubMed ID: 35255986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of decreased dopamine transporter levels on nigrostriatal neurons and paraquat/maneb toxicity in mice.
    Richter F; Gabby L; McDowell KA; Mulligan CK; De La Rosa K; Sioshansi PC; Mortazavi F; Cely I; Ackerson LC; Tsan L; Murphy NP; Maidment NT; Chesselet MF
    Neurobiol Aging; 2017 Mar; 51():54-66. PubMed ID: 28038352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
    Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
    PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short- and long-term effects induced by repeated 6-OHDA intraventricular administration: A new progressive and bilateral rodent model of Parkinson's disease.
    Quiroga-Varela A; Aguilar E; Iglesias E; Obeso JA; Marin C
    Neuroscience; 2017 Oct; 361():144-156. PubMed ID: 28823819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
    Choi DY; Lee MK; Hong JT
    Neurobiol Dis; 2013 Jan; 49():159-68. PubMed ID: 22922220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graded 6-OHDA-induced dopamine depletion in the nigrostriatal pathway evokes progressive pathological neuronal activities in the subthalamic nucleus of a hemi-parkinsonian mouse.
    Park SE; Song KI; Kim H; Chung S; Youn I
    Behav Brain Res; 2018 May; 344():42-47. PubMed ID: 29452192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of Cholesterol and Homocysteine in the Nigrostriatal Pathway of Brain Contributes to the Dopaminergic Neurodegeneration in Mice.
    Paul R; Dutta A; Phukan BC; Mazumder MK; Justin-Thenmozhi A; Manivasagam T; Bhattacharya P; Borah A
    Neuroscience; 2018 Sep; 388():347-356. PubMed ID: 30075243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.